Hoechst Pakistan Limited Stock

Equities

HPL

PK0021801011

Pharmaceuticals

End-of-day quote Pakistan S.E. 06:00:00 2024-04-17 pm EDT 5-day change 1st Jan Change
1,300 PKR -3.70% Intraday chart for Hoechst Pakistan Limited 0.00% +8.33%
Sales 2022 18.56B 66.7M Sales 2023 21.37B 76.8M Capitalization 11.57B 41.6M
Net income 2022 167M 600K Net income 2023 361M 1.3M EV / Sales 2022 0.57 x
Net Debt 2022 1.4B 5.03M Net cash position 2023 1.01B 3.62M EV / Sales 2023 0.49 x
P/E ratio 2022
55.4 x
P/E ratio 2023
32.1 x
Employees 734
Yield 2022 *
-
Yield 2023
2.5%
Free-Float 7.83%
More Fundamentals * Assessed data
Dynamic Chart
Hoechst Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hoechst Pakistan Limited Announces Company Secretary Changes CI
Hoechst Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sanofi-aventis Pakistan Limited will Change its Name to Hoechst Pakistan Limited CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sanofi-aventis Pakistan Limited Announces CEO Changes CI
Sanofi-aventis Pakistan Limited Announces Retirement of Dr. Asim Jamal as Managing Director, Effective June 30, 2023 CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Sanofi Aventis Pakistan Limited Announces Change of Directors CI
The Investor Consortium comprised of Packages Limited, IGI Investments Limited and Ali Gohar & Co. Ltd completed the acquisition of 52.87% stake in sanofi-aventis Pakistan Limited from Sanofi Foreign Participations B.V. CI
Pakistan defers decision on drug price rise as pharma firms struggle RE
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Sanofi-aventis Pakistan Limited Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
More news
1 day-3.70%
1 month+3.17%
6 months+83.10%
Current year+8.33%
More quotes
1 week
1 300.00
Extreme 1300
1 350.00
1 month
1 210.01
Extreme 1210.01
1 354.44
Current year
1 210.01
Extreme 1210.01
1 422.00
1 year
650.00
Extreme 650
1 422.00
3 years
492.00
Extreme 492
1 540.00
5 years
436.20
Extreme 436.2
1 540.00
10 years
436.20
Extreme 436.2
3 000.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 23-04-27
Director of Finance/CFO - -
Chief Operating Officer - -
Members of the board TitleAgeSince
Director/Board Member - 87-02-21
Chairman - 76-12-31
Director/Board Member - 11-02-10
More insiders
Date Price Change Volume
24-04-18 1,300 -3.70% 20
24-04-17 1,350 +3.85% 720
24-04-16 1,300 0.00% 260
24-04-15 1,300 0.00% 300

End-of-day quote Pakistan S.E., April 17, 2024

More quotes
Hoechst Pakistan Limited, formerly Sanofi Aventis Pakistan Limited, is a pharmaceutical company, which is engaged in the manufacturing and selling of pharmaceutical and consumer products. It offers medicines, consumer healthcare products, generics and animal health products. Its products for diabetes include Amaryl, Amaryl MSR, Daonil, Neodipar, Toujeo, Lantus, SoloSTAR and Apidra. Its oncology products include Thyrogen, Jevtana, Taxotere, Eloxatin and Fludara. Its nephrology product is Renvela. Its organ transplantation is Thymoglobuline. Its urology product is Xatral. Its pain management products are No-Spa and Muscoril. Its antiemetic product includes Stemetil. Its allergy management product includes Telfast, Telfast-D, Avil, Nasacort, Phenergan and Tixylix. Its sleep disorder product is Stilnox. Its other products include Haemaccel, Plavix, CoPlavix, Aprovel, CoAprovel, Cordarone, Clexane, Tritace, CoTritace, Winstor, Lasix, Flagyl, Tarivid, Claforan, Aventriax, Orelox, and others.
More about the company